ProCE Banner Activity

Phase III EV-302/KEYNOTE-A39: Subgroup Analyses of EV + Pembrolizumab vs Chemotherapy in Previously Untreated Adv Urothelial Carcinoma

Conference Coverage
Slideset

Subgroup analyses of PFS and OS showed benefit with enfortumab vedotin-ejfv plus pembrolizumab vs platinum-based chemotherapy across all prespecified subgroups and the ITT population from the phase III EV-302/KEYNOTE-A39 trial in previously untreated locally advanced or metastatic urothelial cancer.

Released: February 01, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

AstraZeneca

Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC